FYREMADEL SOLUTION FOR INJECTION 0.25 MG/0.5 ML [SIN17613P]
Active ingredients: GANIRELIX ACETATE EQV GANIRELIX
Product Info
FYREMADEL SOLUTION FOR INJECTION 0.25 MG/0.5 ML
[SIN17613P]
Product information
Active Ingredient and Strength | GANIRELIX ACETATE EQV GANIRELIX - 0.25 MG/0.5 ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | SUN PHARMACEUTICAL INDUSTRIES LIMITED - INDIA |
Registration Number | SIN17613P |
Licence Holder | RANBAXY (MALAYSIA) SDN. BHD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | H01CC01 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1. THERAPEUTIC INDICATIONS
The prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).
In clinical trials FYREMADEL was used with recombinant follicle stimulating hormone (FSH).
Dosing
4.2 DOSE AND METHOD OF ADMINISTRATION
FYREMADEL should only be prescribed by a specialist experienced in the treatment of infertility.
Dose
FYREMADEL is used to prevent premature LH surges in patients undergoing COH. Controlled ovarian hyperstimulation with FSH may start at day 2 or 3 of menses. FYREMADEL (0.25 mg) should be injected subcutaneously once daily, starting in general on day 6 of FSH administration. In high responders an early LH rise may be prevented by starting FYREMADEL treatment on day 5. The start of FYREMADEL may be delayed in absence of follicular growth.
FYREMADEL and FSH should be administered approximately at the same time. However, the preparations should not be mixed and different injection sites are to be used.
FSH dose adjustments should be based on the number and size of growing follicles, rather than on the amount of circulating oestradiol (see section PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES; Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Daily treatment with FYREMADEL should be continued up to the day that sufficient follicles of adequate size are present. Final maturation of follicles can be induced by administering human chorionic gonadotrophin (hCG). Because of the half-life of ganirelix, the time between two FYREMADEL injections as well as the time between the last FYREMADEL injection and the hCG injection should not exceed 30 hrs, as otherwise a premature LH surge may occur. Therefore, when injecting FYREMADEL in the morning, treatment with FYREMADEL should be continued throughout the gonadotrophin treatment period including the day of triggering ovulation. When injecting FYREMADEL in the afternoon the last FYREMADEL injection should be given in the afternoon prior to the day of triggering ovulation.
Ganirelix has been safe and effective in patients undergoing multiple treatment cycles.
Luteal phase support should be given according to the reproductive medical center’s practice.
Method of administration
FYREMADEL should be administered subcutaneously, preferably in the upper leg. The injection site should be varied to prevent lipoatrophy. The patient or her partner may perform the injections of FYREMADEL themselves, provided that they are adequately instructed and have access to expert advice. Air bubble(s) may be seen in the pre-filled syringe. This is expected, and removal of the air bubble(s) is not needed.
Contraindications
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of excipients of the formulation.
Hypersensitivity to gonadotrophin-releasing hormone (GnRH) or any other GnRH analogue.
Moderate or severe impairment of renal or hepatic function
Pregnancy or breast-feeding.
